All In Biotech

NDA 206628 · Hq Spclt Pharma

Dexmedetomidine Hydrochloride

Dexmedetomidine Hydrochloride · Intravenous

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 21, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,922

279 Phase 3, 159 recruiting

FAERS reports

5,243

5,001 serious, 568 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 2, 2026.

Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection is a alpha 2 adrenergic receptor agonist indicated for: • Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection by continuous infusion not to exceed 24 hours. (1.1) • Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. (1.2) 1.1 Intensive Care Unit Sedation Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection is indicated for sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection should be administered by continuous infusion not to exceed 24 hours. 1.2 Procedural Sedation Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection is indicated for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.

Mechanism: Dexmedetomidine is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties. Alpha 2 selectivity was observed in animals following slow intravenous infusion of low and medium doses (10 mcg/kg to 300 mcg/kg). Both alpha 1 and alpha 2 activity is observed following slow intravenous infusion of high doses (greater than or equal to 1000 mcg/kg) or with rapid intravenous administration.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 19, 2016 Supplement 2 · Efficacy LetterLabel
  • Oct 21, 2015 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLetterLabel
4 products under this application
  • DEXMEDETOMIDINE HYDROCHLORIDE · DEXMEDETOMIDINE HYDROCHLORIDE EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • DEXMEDETOMIDINE HYDROCHLORIDE · DEXMEDETOMIDINE HYDROCHLORIDE EQ 1MG BASE/10ML (EQ 100MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DEXMEDETOMIDINE HYDROCHLORIDE · DEXMEDETOMIDINE HYDROCHLORIDE EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • DEXMEDETOMIDINE HYDROCHLORIDE · DEXMEDETOMIDINE HYDROCHLORIDE EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexmedetomidine" as an intervention, any sponsor and status, largest first.

All 1,922 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use608
  • drug ineffective450
  • bradycardia418
  • hypotension313
  • cardiac arrest263
  • drug interaction261
  • agitation202
  • product use in unapproved indication174
  • respiratory failure167
  • delirium153
  • pyrexia146
  • tachycardia146

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20065
20071
20088
200918
201024
201129
201230
201390
2014103
201580
2016220
2017244
2018211
2019348
2020512
2021571
2022552
2023613
2024659
2025582
2026342

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 2, 2026

    Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24). Marketed by WG Critical Care

  • Current · updated Nov 2, 2026

    Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04). Marketed by WG Critical Care

  • Current · updated Nov 2, 2026

    Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24). Marketed by WG Critical Care

  • Current · updated Nov 2, 2026

    Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04). Marketed by WG Critical Care

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,906 on PubMed

Sponsor: Hq Spclt Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.